Author

Lei Diao

Observed name: Diao, Lei

Observed institution: Fosun Pharma (China)

ORCID: 0000-0002-0979-8827

Observed ORCID: 0000-0002-0979-8827

OpenAlex ID: A5011739456

Phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1-related unresectable plexiform neurofibromas

2023 · Xiaojie Hu, Wenbin Li, et al. · BMC Medicine · 20

PDF

A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma

2022 · Lili Mao, Jun Guo, et al. · European Journal of Cancer · 19

Population pharmacokinetic model for oral ORIN1001 in Chinese patients with advanced solid tumors

2024 · Xiaoqing Li, Yunhai Bo, et al. · Frontiers in Pharmacology · 11

PDF

Model‐informed dose selection for an investigational human epidermal growth factor receptor 2 antibody–drug conjugate FS‐1502 in patients with human epidermal growth factor receptor 2‐expressing advanced malignant solid tumours

2023 · Yi Sun, Chao Li, et al. · British Journal of Clinical Pharmacology · 6

PDF

Abstract P4-01-07: FS-1502, an anti-HER2 ADC, in Patients with HER2-Expressing Advanced Solid Tumors: A Phase 1a Dose-Escalation Study

2023 · Qiao Li, Xian Wang, et al. · Cancer Research · 5

Population pharmacokinetics of FCN-159, a MEK1/2 inhibitor, in adult patients with advanced melanoma and neurofibromatosis type 1 (NF1) and model informed dosing recommendations for NF1 pediatrics

2023 · Yan Tan, Ailing Cui, et al. · Frontiers in Pharmacology · 5

PDF

Effect of Food (Low and High Fat) on Pharmacokinetics of FCN-159, a Selective MEK Inhibitor, in Healthy Chinese Males

2023 · Jiangfan Li, Yan Tan, et al. · Advances in Therapy · 5

Pharmacokinetics, safety, and tolerability of nacubactam (OP0595) after intravenous infusion: a randomized, double-blind, placebo-controlled phase I clinical trial in healthy Chinese male subjects

2025 · Hui Qiu, Tingting Wu, et al. · Clinical and Experimental Medicine · 4

Phase 1 Study of Luvometinib Use in Pediatric Patients with Neurofibromatosis Type 1-Related Unresectable Plexiform Neurofibromas

2025 · Xiaojie Hu, Zhuli Wu, et al. · Targeted Oncology · 4

Pharmacokinetics, mass balance, and metabolism of [14C]FCN-437c, a selective and potent CDK4/6 inhibitor in humans

2025 · Lei Gao, Sheng Ma, et al. · Cancer Chemotherapy and Pharmacology · 4

Pharmacokinetics, mass balance, and metabolism of [14C]SAF-189s, a potent anaplastic lymphoma kinase/c-ROS proto-oncogene 1 inhibitor in humans: Metabolism potentially affected by interaction of cytochrome P450 enzymes and intestinal microbiota

2025 · Ming Yang, Lei Diao, et al. · Drug Metabolism and Disposition · 3

Effect of High-Fat Food on the Pharmacokinetic Profile and Safety of SAF-189s, an ALK/ROS1 Inhibitor, in Healthy Chinese Adults

2023 · Huiling Qin, Yan Tan, et al. · Drugs in R&D · 3

PDF

Pharmacokinetics, Safety, and Tolerability of Tenapanor in Healthy Chinese and Caucasian Volunteers: A Randomized, Open-Label, Single-Center, Placebo-Controlled Phase 1 Study

2024 · Gang Yuan, Yili Chen, et al. · International Journal of Clinical Practice · 2

PDF

Abstract P4-01-21: Phase 2 Study of the CDK4/6 Inhibitor FCN-437c in Combination With Fulvestrant or Letrozole and Goserelin in Patients With HR+, HER2– Advanced Breast Cancer

2023 · JiaJie Shi, Wei Li, et al. · Cancer Research · 2

No QTc prolongation with CDK 4/6 inhibitor FCN-437c: results of a concentration-QTc analysis from a dedicated study in adult healthy subjects

2024 · Lin Zhao, Yi Sun, et al. · Frontiers in Pharmacology · 1

PDF

Safety and Pharmacokinetics of PSD502 in Healthy Chinese Male and Female Volunteers: Two Randomized, Double-Blind, Placebo-Controlled, Phase I Trials

2023 · Fangfang Wang, Zhiping Liu, et al. · Clinical Drug Investigation · 1

Population pharmacokinetics and exposure–response analyses of SAF-189s in Chinese patients with ALK+/ROS1+ non-small cell lung cancer

2024 · Yinhui Liu, Yan Tan, et al. · Frontiers in Pharmacology

PDF

Works count: 19

Citation count: 95

H-index: 5

I10-index: 3